传染病信息2024，Vol.37Issue(2) ：164-166.DOI:10.3969/j.issn.1007-8134.2024.02.011

百蕊胶囊治疗新型冠状病毒感染的初步临床观察

Preliminary observation of Bai Rui Capsules in the treatment of patients infected with COVID-19

王霞 李静 唐铭泽 邵欢欢 李永纲
传染病信息2024，Vol.37Issue(2) ：164-166.DOI:10.3969/j.issn.1007-8134.2024.02.011
✕
  • 维普
  • 万方数据

百蕊胶囊治疗新型冠状病毒感染的初步临床观察

Preliminary observation of Bai Rui Capsules in the treatment of patients infected with COVID-19

王霞 1李静 2唐铭泽 1邵欢欢 2李永纲2
扫码查看

作者信息

  • 1. 100176 北京,悦康药业集团药物研究院
  • 2. 100039 北京,国家感染性疾病临床医学研究中心(北京)
  • 折叠

摘要

目的 本研究旨在回顾性分析百蕊胶囊治疗新型冠状病毒感染的临床可行性及其治疗效果,为进一步改善这类患者的预后提供了中医药治疗的有力证据.方法 将 2022 年 11 月 26 日—12 月 13 日感染新型冠状病毒的 282 例悦康药业员工纳入研究,按照治疗给药方案的不同将研究对象分为4 组:常规治疗组(40 例)、百蕊胶囊单药组(85 例)、百蕊胶囊联合复方氨酚烷胺胶囊治疗组(95 例)及百蕊胶囊联合对症治疗组(62 例).本研究采用SAS 9.4 软件,对比分析了4 组患者在核酸/抗原转阴时间、发热持续时间、咳嗽消失时间、乏力消失时间以及其他症状减轻时间等方面的表现,以评估各治疗组间的差异及百蕊胶囊的临床疗效.结果 与常规治疗组相比,给药方案包含百蕊胶囊的 3 个治疗组在缩短核酸/抗原转阴时间、减少发热持续时间以及咳嗽消失时间等方面均表现出显著优势(P均＜0.05),在缩短新型冠状病毒核酸/抗原转阴时间和减少发热持续时间方面,百蕊胶囊联合复方氨酚烷胺胶囊治疗组表现出相比其他治疗组的显著优势.本次研究过程中未发现与百蕊胶囊用药相关的不良反应.结论 百蕊胶囊的临床应用有助于缩短新型冠状病毒患者的核酸/抗原转阴时间、减少发热持续时间以及咳嗽消失时间等,且安全性良好.

Abstract

Objective This study aimed to retrospectively analyze the clinical feasibility and therapeutic effects of Bai Rui Capsules in the treatment of patients infected with the novel coronavirus(COVID-19),providing strong evidence of traditional Chinese medicine treatment to further improve the prognosis of such patients.Methods A total of 282 employees from YOUCARE Pharmaceutical who were infected with the novel coronavirus between November 26th and December 13th,2022,were retrospectively included in this study.According to different treatment regimens,the subjects were divided into 4 groups:the conventional treatment group(40 cases),Bai Rui Capsule monotherapy group(85 cases),Bai Rui Capsule combined with compound paracetamol and amantadine hydrochloride capsules treatment group(95 cases),and Bai Rui Capsule combined with symptomatic treatment group(62 cases).A comparative analysis of the nucleic acid/antigen negative conversion time,the duration of fever,cough resolution time,fatigue resolution time,and the time to amelioration of other symptoms among the four groups of patients was conducted to evaluate the clinical efficacy of Bai Rui Capsules.Results Compared to the conventional treatment group,the 3 groups containing Bai Rui Capsules showed significant advantages in shortening the nucleic acid/antigen negative conversion time,reducing the duration of fever,and time to cough resolution(P＜0.05).The Bai Rui Capsule combined with compound paracetamol and amantadine hydrochloride capsules treatment group showed a significant superiority in shortening the nucleic acid/antigen negative conversion time and reducing the duration of fever compared to the other treatment groups.No adverse reactions related to the use of Bai Rui Capsules were observed during this study.Conclusion The clinical application of Bai Rui Capsules can help shorten the nucleic acid/antigen negative conversion time,reduce the duration of fever and cough disappearance time in patients infected with the novel coronavirus,and has good safety.

关键词

新型冠状病毒感染/百蕊胶囊/中西医结合/疗效评估

Key words

COVID-19/Bai Rui Capsules/integrated chinese and western medicine/efficacy evaluation

引用本文复制引用

出版年

2024
传染病信息
解放军第三0二医院

传染病信息

CSTPCD
影响因子：1.366
ISSN：1007-8134
段落导航相关论文